Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L6 pseudogene 23 is classified as a pseudogene, which means it is a genomic DNA sequence similar to a functional gene but generally non-functional; it does not produce a functional protein. RPL6P23 is related by sequence to the gene encoding ribosomal protein L6, an essential component of the 60S ribosomal subunit, but RPL6P23 itself is not expressed as a protein and does not have a known biological or disease-associated function in humans. It is not considered a therapeutic target, and there are no known drugs, biomarkers, or safety concerns associated with it. RPL6P23 was catalogued based on its sequence similarity to the functional RPL6 gene, but functions only as a processed pseudogene and not as an active gene product. There is no evidence or mention in scientific resources of direct involvement in disease, drug interaction, or other cellular functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L6 pseudogene 23 (RPL6P23).